West Pharmaceutical Services/$WST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About West Pharmaceutical Services
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Ticker
$WST
Sector
Primary listing
NYSE
Employees
10,600
Headquarters
Website
WST Metrics
BasicAdvanced
$20B
41.80
$6.68
1.05
$0.84
0.30%
Price and volume
Market cap
$20B
Beta
1.05
52-week high
$348.90
52-week low
$187.43
Average daily volume
656K
Dividend rate
$0.84
Financial strength
Current ratio
2.78
Quick ratio
1.852
Long term debt to equity
9.764
Total debt to equity
10.522
Dividend payout ratio (TTM)
12.32%
Interest coverage (TTM)
1,568.00%
Profitability
EBITDA (TTM)
795.6
Gross margin (TTM)
35.27%
Net profit margin (TTM)
16.48%
Operating margin (TTM)
21.39%
Effective tax rate (TTM)
20.21%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
10.64%
Return on equity (TTM)
17.72%
Valuation
Price to earnings (TTM)
41.795
Price to revenue (TTM)
6.843
Price to book
6.86
Price to tangible book (TTM)
7.15
Price to free cash flow (TTM)
58.883
Free cash flow yield (TTM)
1.70%
Free cash flow per share (TTM)
4.745
Dividend yield (TTM)
0.30%
Forward dividend yield
0.30%
Growth
Revenue change (TTM)
2.90%
Earnings per share change (TTM)
-5.00%
3-year revenue growth (CAGR)
0.36%
10-year revenue growth (CAGR)
7.77%
3-year earnings per share growth (CAGR)
-9.33%
10-year earnings per share growth (CAGR)
14.74%
3-year dividend per share growth (CAGR)
5.34%
10-year dividend per share growth (CAGR)
6.80%
What the Analysts think about WST
Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.
Bulls say / Bears say
Q2 2025 net sales rose 9.2% year-over-year to $766.5 million and adjusted diluted EPS reached $1.84, resulting in gross margin expansion to 35.7% and operating margin at 20.1% (Investing.com).
Management raised full-year 2025 guidance to $3.04–$3.06 billion in net sales (up from $2.945–$2.975 billion) and $6.65–$6.85 adjusted EPS (from $6.15–$6.35), signaling confidence in ongoing robust demand (Investing.com).
GLP-1 elastomer products contributed 8% of total revenue and high-value product components grew by 11.3%. KeyBanc reaffirmed its Overweight rating on West due to its near-total participation in injectable GLP-1 capacity expansion projects (Investing.com).
Contract-manufacturing segment grew just 3.0% year-over-year to $146.7 million in Q2 2025, highlighting slower growth outside the company’s higher-margin proprietary products segment (Investing.com).
In Q1 2025, organic net sales increased only 2.1% while adjusted diluted EPS declined to $1.45 from $1.56 a year earlier, emphasizing uneven demand momentum and margin pressure resulting from restructuring and lower-value product mix (Investing.com).
West continues to expect $20–25 million in tariff-related costs and remains vulnerable to currency fluctuations, factors that could pressure margins in the future despite recent foreign-exchange benefits (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
WST Financial Performance
Revenues and expenses
WST Earnings Performance
Company profitability
WST News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for West Pharmaceutical Services stock?
West Pharmaceutical Services (WST) has a market cap of $20B as of October 22, 2025.
What is the P/E ratio for West Pharmaceutical Services stock?
The price to earnings (P/E) ratio for West Pharmaceutical Services (WST) stock is 41.8 as of October 22, 2025.
Does West Pharmaceutical Services stock pay dividends?
Yes, the West Pharmaceutical Services (WST) stock pays dividends to shareholders. As of October 22, 2025, the dividend rate is $0.84 and the yield is 0.3%. West Pharmaceutical Services has a payout ratio of 12.32% on a trailing twelve-month basis.
When is the next West Pharmaceutical Services dividend payment date?
The next West Pharmaceutical Services (WST) dividend payment is scheduled for November 19, 2025.
What is the beta indicator for West Pharmaceutical Services?
West Pharmaceutical Services (WST) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.